FDA Combo Product Letters Tackle Postmarketing Issues; Guidance Planned
Executive Summary
FDA's Office of Combination Products plans to issue guidance on postmarketing requirements included in "request for designation" letters
You may also be interested in...
FDA Combo Approvals Could Follow Drug-Eluting Stent Template
FDA should use its approval of drug-eluting stents as the template for combination product approvals, attendees recommended at FDA's drug delivery workshop July 8 in Bethesda, Md
FDA Combo Approvals Could Follow Drug-Eluting Stent Template
FDA should use its approval of drug-eluting stents as the template for combination product approvals, attendees recommended at FDA's drug delivery workshop July 8 in Bethesda, Md
FDA Combination Product Review Policy Update Includes Tracking System
FDA drug and biologic reviewers should track consultative or collaborative reviews on combination products through each center's tracking system, a Feb. 14 update to the agency's policies and procedures states